Central nervous system (CNS) disorders
Seroxat/Paxil is a selective serotonin reuptake inhibitor (SSRI) approved for depression, panic, obsessive compulsive disorder and social anxiety disorder, with approvals being obtained for generalised anxiety disorder and post traumatic stress disorder.

Wellbutrin is also an anti-depressant, available in the USA in normal or sustained release tablet formulations.

Imigran/Imitrex is a 5HT₁ receptor agonist used for the treatment of severe or frequent migraine and cluster headache, and has become the reference product in this sector. Naramig/Amerge is the Group’s newer migraine product.

Lamictal is a treatment for epilepsy. Used alone or in combination with other products, it has achieved penetration of this mature market through successful treatment of severe cases.

Requip is a specific dopamine D2-like receptor for the treatment of Parkinson’s disease.

Zyban is a novel, nicotine-free prescription medicine, available as a sustained-release tablet, for treating the problem of smoking addiction.

Respiratory
Serevent is a long-acting bronchodilator, and Ventolin a selective short-acting bronchodilator, for the treatment of asthma.

Flixotide/Flovent and Becotide/Beclovent are inhaled steroids for the treatment of inflammation associated with bronchial asthma and chronic bronchitis.

Seretide/Advair, a combination of Serevent and Flixotide, offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler.

Flixonase/Flonase and Beconase are intra-nasal preparations for the treatment of perennial and seasonal rhinitis.

The Group’s respiratory products are now available in a wide choice of delivery systems, including the Diskus/Accuhaler, a dry powder multi-dose inhaler.


Anti-bacterials
The Group markets a range of antibiotics.

Augmentin is a broad-spectrum antibiotic suitable for the treatment of a wide range of common bacterial infections, and is particularly effective against respiratory tract infections.

Zinnat is an oral antibiotic used primarily for community-acquired infections of the lower respiratory tract. Fortum and Zinacef are used in the hospital-based injectable antibiotics market.

Anti-virals
Combivir, a combination of Retrovir and Epivir, has consolidated the position of these two reverse transcriptase inhibitors as the cornerstone of many multiple anti-HIV product regimens. Physician acceptance has clearly demonstrated the value placed on minimising the ‘pill burden’ faced by patients.

Ziagen is the Group’s new reverse transcriptase inhibitor. The product’s potency, ease of use and resistance profile will allow it to play a significant role in a variety of highly active, well tolerated, and simplified HIV treatment regimens.

Trizivir is a combination of Combivir and Ziagen, combining three anti-HIV therapies in one tablet, for twice daily administration.

Agenerase is a new protease inhibitor for the treatment of HIV, the first medicine of this class to be brought to the market by GlaxoSmithKline. Agenerase has a twice daily dosing regime and no significant food or drink restrictions.

Zeffix has been approved for marketing in the USA, Europe, China and other markets for the treatment of chronic hepatitis B.

Zovirax is used for the treatment of herpes infections such as chicken pox, genital herpes, shingles and cold sores. The newer anti-herpes compound, Valtrex, reinforces the Group’s presence in this market as a treatment for zoster and the episodic and long-term suppression of genital herpes.

Relenza, the Group’s novel treatment for influenza, is the first of a new class of drug known as a neuraminidase inhibitor, and targets the primary site of viral replication through direct delivery to the airways via an inhaler.

Metabolic and gastro-intestinal
Avandia is the most potent of a novel class of oral anti-diabetic agents called thiazolidinediones or PPAR-gamma agonists, for the treatment of type 2 diabetes.

Zantac, for the treatment of peptic ulcer disease and a range of gastric acid related disorders, continues to play a major role in treatment in a number of markets, even where patent protection has been lost. Pylorid/Tritec is used, in combination with antibiotics, for the eradication of helicobacter pylori, a causative agent in ulcers.

Lotronex, a novel treatment for the multiple symptoms of irritable bowel syndrome, was approved for use in the USA following priority review and launched in 2000, but was subsequently withdrawn following discussions with the US Food and Drug Administration over the interpretation of data relating to gastro-intestinal side effects.

Vaccines
GlaxoSmithKline markets a range of hepatitis vaccines. Havrix protects against hepatitis A and Engerix-B against hepatitis B. Twinrix is a combined hepatitis A and B vaccine, protecting against both diseases with one vaccine and available in both adult and paediatric strengths.

Infanrix is a range of paediatric vaccine combinations. Infanrix provides protection against diphtheria, tetanus and pertussis (whooping cough). Infanrix PeNta provides additional protection against hepatitis B and polio, and Infanrix HeXa further adds protection against haemophilus influenzae type b, which causes meningitis.

Additionally GlaxoSmithKline markets Priorix, a measles, mumps and rubella vaccine, Typherix, a vaccine for protection against typhoid fever, LYMErix, a vaccine for protection against LYME disease.

Oncology and emesis
Zofran is used to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer, and is available in both oral and injectable forms. It is also approved for use in the prevention and treatment of post-operative nausea and vomiting.

Hycamtin is a second line treatment both for ovarian cancer and for small cell lung cancer.

Panorex is the first monoclonal antibody to be licensed for cancer therapy.

Cardiovascular
Coreg is a blocking agent which has been proven to be effective in treating mild and moderate congestive heart failure.

Dermatologicals
The Group’s principal dermatological products, Betnovate, the higher potency Dermovate and the newer Cutivate are anti-inflammatory steroid products used to treat skin diseases such as eczema and psoriasis.

Divested products
In accordance with agreements for regulatory approvals of the merger between Glaxo Wellcome and SmithKline Beecham, the products Kytril, for the treatment of chemotherapy – and radiotherapy – induced nausea and vomiting, and Famvir, an anti-viral for the treatment of shingles and herpes, were divested in December 2000.

Products – Consumer Healthcare
GlaxoSmithKline’s principal consumer products are presently directed to three major areas. An analysis of sales by these areas is set out below:

Over-the-counter medicines
The most significant products are Panadol, a widely available non-aspirin analgesic; the smoking cessation products Nicorette, NicoDerm CQ, NiQuitin CQ and Nicabate; Tums, the calcium-based antacid and Tagamet HB for the prevention and relief of heartburn; Contac and the Beechams range for the treatment of colds and influenza; and a variety of vitamin and tonic products led by Abtei in Germany. Consumer Healthcare will market additionally OTC versions of Zantac and Beconase.


Oral care
The leading oral care products are Aquafresh, Macleans and Odol toothpastes and toothbrushes sold under the Aquafresh and Dr Best trademarks.


Nutritional healthcare
In this category the principal products are Lucozade, the glucose energy drink; Ribena, a line of juice drinks rich in vitamin C; and Horlicks, a range of milk-based malted food and chocolate drinks.


Block Drug
In January 2001 GlaxoSmithKline completed the acquisition of Block Drug. This will add to the product range Sensodyne toothpaste, Poli-Grip denture adhesive and Polident denture cleaner.